Inventor
LOTTA LUCA ANDREA
US12 patents
⚠️ This page may combine multiple inventors who share the name “LOTTA LUCA ANDREA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
11 patentsUS11957704B2Apr 16, 2024
Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors
REGENERON PHARMA2 citations70
US11939635B2Mar 26, 2024
Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)
REGENERON PHARMA2 citations70
US11759476B2Sep 19, 2023
Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors
REGENERON PHARMA2 citations70
US12123001B2Oct 22, 2024
Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitors
REGENERON PHARMA0 citations57
US12234460B2Feb 25, 2025
Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
REGENERON PHARMA0 citations54
US12018259B2Jun 25, 2024
Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors
REGENERON PHARMA0 citations54
US11891607B2Feb 6, 2024
Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
REGENERON PHARMA0 citations54
US11773393B2Oct 3, 2023
Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors
REGENERON PHARMA0 citations54
US12049670B2Jul 30, 2024
Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof
REGENERON PHARMA0 citations49
US12378557B2Aug 5, 2025
Treatment of sepsis with PCSK9 and LDLR modulators
REGENERON PHARMA0 citations46
US12215322B2Feb 4, 2025
Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors
REGENERON PHARMA0 citations41